211 related articles for article (PubMed ID: 27403912)
21. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
22. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
[TBL] [Abstract][Full Text] [Related]
23. High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study.
Mehrnoush L; Alavian SM; Sharafi H; Behnava B; Salimi S; Keshvari M
Pediatr Hematol Oncol; 2015; 32(6):399-405. PubMed ID: 26086432
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
European Union HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
[TBL] [Abstract][Full Text] [Related]
25. A micro-elimination approach to addressing hepatitis C in Turkey.
Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
[TBL] [Abstract][Full Text] [Related]
26. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
27. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
Elefsiniotis IS; Pavlidis C; Ketikoglou I; Koutsounas S; Scarmeas N; Pantazis KD; Moulakakis A; Tsianos EV
Eur J Intern Med; 2008 Jun; 19(4):266-70. PubMed ID: 18471675
[TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
[TBL] [Abstract][Full Text] [Related]
29. Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
Pawlowska M
Expert Opin Drug Saf; 2015 Mar; 14(3):343-8. PubMed ID: 25599750
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
31. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
Corti G; Salomoni E; Baragli F
Int J Infect Dis; 2014 Feb; 19():85-6. PubMed ID: 24246771
[TBL] [Abstract][Full Text] [Related]
32. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
Honda T; Ishigami M; Masuda H; Ishizu Y; Kuzuya T; Hayashi K; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Urano F; Yoshioka K; Toyoda H; Kumada T; Katano Y; Goto H
J Gastroenterol Hepatol; 2015 Feb; 30(2):321-8. PubMed ID: 25091027
[TBL] [Abstract][Full Text] [Related]
33. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
34. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
35. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin.
Viganò M; Aghemo A; Iavarone M; Rumi MG; Agnelli F; Lampertico P; Donato MF; Colombo M
Antivir Ther; 2009; 14(6):789-96. PubMed ID: 19812441
[TBL] [Abstract][Full Text] [Related]
36. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
[TBL] [Abstract][Full Text] [Related]
37. [Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy].
Cianciara J; Jabłońska J; Horban A; Walewska-Zielecka B
Przegl Epidemiol; 2005; 59(2):385-94. PubMed ID: 16190545
[TBL] [Abstract][Full Text] [Related]
38. [Hepatitis C--treatment of untreated (naive) patients].
Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of individualized treatment for hepatitis C patients in the real world.
Chen TM; Huang PT; Lin CH; Tsai MH; Lin LF; Liu CC; Ho KS; Tung JN
J Gastroenterol Hepatol; 2010 Jan; 25(1):61-9. PubMed ID: 19780879
[TBL] [Abstract][Full Text] [Related]
40. [Triple combination treatment of chronic hepatitis C].
Husa P
Vnitr Lek; 2012; 58(7-8):588-90. PubMed ID: 23067190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]